Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4196 trials
Conditions Glaucoma
Phase PHASE2
Enrollment 125
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-03
Study Details Design, interventions, and primary outcomes

About This Study

Glaucoma, a chronic degenerative disease of the optic nerve, is the leading cause of irreversible blindness worldwide. Although lowering the intraocular pressure (IOP) has been shown to be effective to slow optic nerve degeneration, a significant portion of glaucoma patients continue to develop progressive loss in vision despite adequate control of IOP. Development of neuroprotective therapy to prevent optic nerve degeneration by mechanisms other than IOP- lowering is critical to reduce the burden of glaucoma blindness. With 76 million glaucoma patients in 2020 worldwide, the need to investigate neuroprotection for glaucoma is pressing. While metformin is a widely adopted oral hypoglycemic medication for treatment of type 2 diabetes mellitus (DM), increasing evidence from clinical studies has shown that metformin can decrease the risk of many age-related diseases including neurodegenerative diseases. In a retrospective study of 150,016 patients with DM, those taking metformin at \>1500mg/day had a 25% reduced risk of development of open-angle glaucoma than those who took no metformin. Metformin has a high safety profile. The investigators aim to investigate whether metformin can be repurposed to a neuroprotective therapy for glaucoma patients in a randomized controlled trial. The investigators propose to conduct a 24-month, double-blind, placebo-controlled, parallel group, randomizing 125 primary open angle glaucoma patients who have progressive retinal nerve fiber layer (RNFL) and/or ganglion cell inner plexiform layer (GCIPL) thinning in at least one eye, as determined by optical coherence tomography Trend-based Progression Analysis (TPA) or Guided Progression Analysis (GPA), to receive metformin 1500mg/day or placebo. All patients will be followed up at 2-month intervals for IOP, RNFL thickness, and visual field (VF) measurements. The objectives are to compare (1) the rates of change of average RNFL thickness (primary outcome measure), and (2) the rates of change of VF mean deviation (MD) (secondary outcome measure) between treatment groups. The investigators hypothesize that patients treated with metformin have a slower rate of RNFL thinning, and a slower rate of VF MD decline compared with those treated with placebo at similar levels of IOP over the 24-month follow-up. The proposed study has the potential to mark a paradigm shift in the management of glaucoma patients by demonstrating that neuroprotection is attainable with metformin, which will alleviate the increasing burden of glaucoma blindness in China and other Asian countries where glaucoma patients with normal levels of IOP are prevalent. Furthermore, it will inform and impact the study design in future neuroprotection trials which can expedite the development of neuroprotective therapy for glaucoma.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Drug: Metformin — Patients randomized to metformin treatment will take 750 mg Metformin Hydrochloride tablets once daily for 4 weeks; the dose will be increased to 750 mg twice daily for the rest of the study period.
  • Drug: Placebo — Patients randomized to placebo group treatment will take identical-appearing placebo tablets once daily for 4 weeks; and twice daily for the rest of the study period.

Primary Outcomes

  • Rates of RNFL/GCIPL thinning (Evaluation of Neuroprotection) (24 months)
  • Change in visual field sensitivity (Evaluation of Neuroenhancement) (4 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-06-01
Completion: 2027-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 125 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Christopher Kai Shun Leung
Principal Investigators:
  • Christopher LEUNG, MD (PRINCIPAL_INVESTIGATOR) - The University of Hong Kong
Contact Information
Study Contact:
Christopher LEUNG, MD
(852)3962-1405
cleung21@hku.hk
Nate CHAN
(852)3910-3906
natechan@hku.hk
Gilda LAI
(852)3910-2672
HKU Eye Centre
Interventions
  • Drug: Metformin — Patients randomized to metformin treatment will take 750 mg Metformin Hydrochloride tablets once daily for 4 weeks; the dose will be increased to 750 mg twice daily for the rest of the study period.
  • Drug: Placebo — Patients randomized to placebo group treatment will take identical-appearing placebo tablets once daily for 4 weeks; and twice daily for the rest of the study period.
Study Locations (1 sites)
HKU Eye Centre, Wong Chuk Hang, Hong Kong
Eligibility Criteria
Inclusion Criteria: * age ≥18 years * best corrected VA ≥20/40 * IOP ≤24mmHg at the screening and baseline visits * progressive RNFL and/or GCIPL thinning by TPA or GPA over the past 3 years in at least one eye. Exclusion Criteria: * patients with DM, kidney or liver diseases * pathological myopia * cognitive impairment (e.g. Alzheimer's disease) * diseases that may cause visual field loss or optic disc abnormalities other than glaucoma * inability to perform reliable visual field * suboptimal quality of OCT images. Both eyes of a patient will be included in the analysis if both eyesare eligible for inclusion.
Conditions Pregnancy, Pre-eclampsia
Phase NA
Enrollment 2000
Locations 8 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-03
Study Details Design, interventions, and primary outcomes

About This Study

Background: Multiple adaptations at the cardiovascular system occurs during pregnancy. In the pregnancy condition pre-eclampsia (PE), this adaptations are abnormal. Five to eight percent of all pregnant women worldwide will develop PE. PE is a pregnancy condition which is characterized with a high blood pressure (\>140/90 mm Hg) and the occurrence of proteinuria (\>3g/dl/24h) after 20 weeks of gestation. When untreated, this condition can have severe complications for both mother and child. It's important to monitor women with a high risk for developing PE for an early detection and treatment of this condition. For this reason, a multicenter study is set up with the following applications: 1. NICCOMO and Maternal Venous Doppler Echography: impedance cardiograph and an echography of the heart and veins. 2. Maltron: bio-electronic impedance analyze 3. Remote monitoring of the high risk patients to become a more intensive follow-up Number of inclusions: 2000 pregnant women from the prenatal consultations of eight different hospitals:

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Device: remote monitoring — Intervention Description: Patients can participate in the study when they're 10 weeks pregnant. At 10 weeks: a NICCOMO, Maternal Venous Doppler Echography and Maltron measurement will be taken. This measurement will be repeated at 20 weeks of pregnancy, and 30 weeks of pregnancy when they're aberrant. When the measurements are abnormal, the patients will be included in the remote monitoring study. The following protocol and devices will be applied: Device What When Withings Wireless Blood Pressure Monitor Blood Pressure 2x/day Withings Pulse O² Activity Day and night Withings Smart Body Analyzer Weight 1x/day

Primary Outcomes

  • Niccomo measurement (10 weeks of pregnancy)
  • Niccomo measurement (20 weeks of pregnancy)
  • Systolic and Diastolic Blood pressure monitoring (10 weeks of pregnancy)
  • Systolic and Diastolic Blood pressure monitoring (20 weeks of pregnancy)
  • a maternal Venous Doppler Echochraphy (10 weeks of pregnancy)
  • Maltron measurement (10 weeks of pregnancy)
  • a maternal Venous Doppler Echochraphy (20 weeks of pregnancy)
  • Maltron measurement (20 weeks of pregnancy)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2016-05
Completion: 2030-12
Eligibility
Age: 18 Years – 50 Years
Sex: FEMALE
Volunteers: true
Enrollment: 2000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Hasselt University
Collaborators: Ziekenhuis Oost-Limburg
Principal Investigators:
  • Wilfried Gyselaers, prof. dr. (PRINCIPAL_INVESTIGATOR) - Hasselt University
  • Nele Geusens, dr. (STUDY_CHAIR) - Ziekenhuis Oost-Limburg
Contact Information
Study Contact:
Dorien Lanssens, drs.
dorien.lanssens@uhasselt.be
Dorien Lanssens, drs.
Ziekenhuis Maas en Kempen
Dorien Lanssens, drs.
dorien.lanssens@uhasselt.be
Ziekenhuis Oost-Limburg
Interventions
  • Device: remote monitoring — Intervention Description: Patients can participate in the study when they're 10 weeks pregnant. At 10 weeks: a NICCOMO, Maternal Venous Doppler Echography and Maltron measurement will be taken. This measurement will be repeated at 20 weeks of pregnancy, and 30 weeks of pregnancy when they're aberrant. When the measurements are abnormal, the patients will be included in the remote monitoring study. The following protocol and devices will be applied: Device What When Withings Wireless Blood Pressure Monitor Blood Pressure 2x/day Withings Pulse O² Activity Day and night Withings Smart Body Analyzer Weight 1x/day
Study Locations (8 sites)
Ziekenhuis Maas en Kempen, Bree, Belgium
Ziekenhuis Oost-Limburg, Genk, 3600 Belgium
Jessa Ziekenhuis, Hasselt, 3500 Belgium
Sint-Fransiscus Ziekenhuis, Heusden-Zolder, Belgium
Heilig Hart Ziekenhuis, Mol, Belgium
Mariaziekenhuis Oost-Limburg, Overpelt, Belgium
Sint-Trudo ziekenhuis, Sint-Truiden, Belgium
AZ-vesalius, Tongeren, Belgium
Eligibility Criteria
Inclusion Criteria: * \> 10 weeks of pregnancy, primipara and multipara Exclusion Criteria: * \< 10 weeks of pregnancy and congenital malformations of the fetus
Conditions Pulmonary Embolism, Chronic Thromboembol...
Phase Not Applicable
Enrollment 1500
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-03
Study Details Design, interventions, and primary outcomes

About This Study

The CHinese pulmOnary Embolism Multimodality Imaging-artifiCial intelligencE Study (CHOICE) is a prospective observational multi-center study that will collect imaging text data and raw data of patients with pulmonary embolism (PE) in China. By combining artificial intelligence technology, it aims to identify imaging markers to assist in early diagnosis, differential diagnosis, risk stratification, and prognosis assessment of PE.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Device: Artificial Intelligence — AI technology will provide novel imaging markers and generate a radiology report with relevant key slice imaging and evaluation results

Primary Outcomes

  • Diagnostic rate of PE (2 years)
  • APE risk stratification rates (low, intermediate low, intermediate high and high risk) (2 years)
  • Disease severity of chronic thromboembolic pulmonary disease (CTEPD)/chronic thromboembolic pulmonary hypertension (CTEPH) (2 years)
  • 30 day mortality (2 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2010-09-01
Completion: 2028-09-01
Eligibility
Age: 14 Years and older
Sex: ALL
Volunteers: false
Enrollment: 1500 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: China-Japan Friendship Hospital
Principal Investigators:
  • Zhenguo Zhai, PhD (STUDY_DIRECTOR) - China-Japan Friendship Hospital
Contact Information
Study Contact:
Min Liu, PhD
+86-10-84205056
mikie0763@126.com
Min Liu, PhD
+86-10-84205056
mikie0763@126.com
China-Japan Frendship hospital
Zhenguo Zhai, PhD
+86-10-84206269
zhaizhenguo2011@126.com
China-Japan Frendship hospital
Interventions
  • Device: Artificial Intelligence — AI technology will provide novel imaging markers and generate a radiology report with relevant key slice imaging and evaluation results
Study Locations (1 sites)
China-Japan Frendship hospital, Beijing, 100029 China
Eligibility Criteria
Inclusion Criteria: * 14 Years and older * Patients suspected of PE Exclusion Criteria: * Pregnant women * Refuse to follow up * Incomplete or discontinued imaging scans * Insufficient quality of image data to allow for analysis
Conditions sFlt1 Mediated Preterm Preeclampsia, Pre...
Phase PHASE1
Enrollment 60
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-03
Study Details Design, interventions, and primary outcomes

About This Study

This study is a dose finding study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of subcutaneous CBP-4888 in hospitalized participants with Preterm Preeclampsia receiving Standard of Care, Expectant Management. Eligible participants are between 26 +0/7 and 35 +6/7 weeks gestational age and clinically appropriate for inpatient expectant management. Eligible participants will receive standard of care expectant management for their pregnancy with the only study interventions being one subcutaneous dose of CBP-4888. Participants will: * receive a single subcutaneous injection dose of CBP-4888 and will be followed through delivery and for 42 days (+14 days) after delivery. Participants will be followed through 6 weeks post delivery. * Infants will be evaluated immediately postpartum and then followed through 24 months of age with standard infant and pediatric assessments with phone calls made to parents.

Design

Study type: Interventional Phases: Phase1 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: CBP-4888 — Participants will receive a subcutaneous dose of CBP-4888. Dosing is weight based using the participant's first trimester weight.

Primary Outcomes

  • Incidence of treatment emergent events and adverse events of special interest when CBP-4888 is administered to pregnant participants (6 weeks postpartum)
  • Determine recommended phase 2 dose (From pre-dose on Day 1 through the last measurable concentration at approximately 72 hours postpartum in serum)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2025-02-26
Completion: 2029-03-31
Eligibility
Age: 18 Years – 45 Years
Sex: FEMALE
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Comanche Biopharma
Contact Information
Study Contact:
Aparna Shah, MD
248-520-7361
ashah@comanchebiopharma.com
Shaun Brennecke, MD
s.brennecke@unimelb.edu.au
The Royal Women's Hospital
Maddie Kendall
0456 409 087
madeleine.kendall@monash.edu
Monash University
Interventions
  • Drug: CBP-4888 — Participants will receive a subcutaneous dose of CBP-4888. Dosing is weight based using the participant's first trimester weight.
Study Locations (3 sites)
The Royal Women's Hospital, Parkville, Victoria 3052 Australia
Monash University, Melbourne, Australia
Royal Melbourne, Melbourne, Australia
Eligibility Criteria
Inclusion Criteria: * Hospitalized with a hypertensive disorder of pregnancy (preeclampsia) defined by elevated blood pressure after 20 weeks gestation with proteinuria or, in the absence of proteinuria, with evidence of organ dysfunction (e.g., thrombocytopenia, renal insufficiency, or impaired liver function), and expected to remain hospitalized through delivery * The subject has given written consent to participate in the study. * Pregnant participants aged 18 to 45 years of age * Gestational age at Day 1 between 26 weeks 0/7 days and 35 weeks 6/7 days * Deemed clinically stable and suitable for expectant management for at least 72 hours post CBP-4888 administration * The woman carries a singleton pregnancy * Anticipate that hospitalization will continue through delivery Exclusion Criteria: * Placenta previa, abruption, accreta, or persistent unexplained vaginal bleeding. * Fetal growth restriction (\<3rd percentile, or \<10th percentile with abnormal Doppler) or known major chromosomal/genetic abnormalities. * Maternal conditions requiring immediate delivery (e.g., severe hypertension, eclampsia, non-reassuring fetal status, pulmonary edema). * Known active maternal infections considered to potentially affect placental function. * Significant maternal medical conditions (e.g., HELLP syndrome, advanced kidney disease, severe cardiac disease, uncontrolled neurological disorder, lupus with nephritis/cerebritis). * Use of another investigational drug within 30 days prior to study entry. * Any other condition that, in the investigator's judgment, poses risk to mother or fetus.
Conditions Breast Carcinoma, Cervical Carcinoma, Co...
Phase NA
Enrollment 2067
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-03
Study Details Design, interventions, and primary outcomes

About This Study

This clinical trial develops and tests how well a multi-level intervention (MLI), The Ohio State University (OSU) SCREEN Community Program, works to increase screening and follow-up for breast, cervical and colorectal (CRC) cancer among low-income and un/underinsured female residents in three counties in Central Ohio. In Ohio, incidence and mortality rates for breast, cervical and CRC are higher than or similar to the national average; in addition, underserved populations - minority, rural and low-income women - have higher rates of these cancers. Screening can detect precancerous colorectal and cervical lesions and other early-stage cancers when treatment is less intensive and more successful and is known to reduce mortality rates for breast, cervical, and CRC, however many of these women lack access to health care and screenings. This MLI includes clinic-based components, such as patient education, as well as community-based strategies, such as media programs and training health workers, that can increase rates of guideline-recommended breast, cervical and CRC screening and follow-ups in underserved populations. The OSU SCREEN Community Program may be an effective way to improve breast, cervical and CRC screenings among underserved women in Ohio.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Sequential Primary purpose: Screening Masking/blinding: None

Interventions / Regimen

  • Other: Cancer Screening — Undergo cancer screening
  • Other: Discussion — Participate in discussions
  • Other: Educational Activity — Receive coaching calls
  • Other: Educational Intervention — Receive educational materials
  • Behavioral: Focus Group — Participate in focus group
  • Other: Health Care Delivery — Integrate new activities into usual clinic processes
  • Other: Health Promotion — Promote screening and wellness visits
  • Other: Health Promotion and Education — Participate in educational sessions

Primary Outcomes

  • Up to date (UTD) status for all three screenings (Early Intervention Wave) (At baseline and at the end of the Implementation Phase (up to 4 years))
  • Status of follow-up for abnormal tests (Early Intervention Wave) (At baseline and at the end of the Implementation Phase (up to 4 years))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-03-12
Completion: 2029-12-31
Eligibility
Age: Not reported
Sex: ALL
Volunteers: true
Enrollment: 2067 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Ohio State University Comprehensive Cancer Center
Collaborators: American Cancer Society, Inc.
Principal Investigators:
  • Electra D Paskett, PhD (PRINCIPAL_INVESTIGATOR) - Ohio State University Comprehensive Cancer Center
Contact Information
Study Contact:
The Ohio State University Comprehensive Cancer Center
800-293-5066
OSUCCCClinicaltrials@osumc.edu
Electra D. Paskett, PhD
614-293-3917
Electra.Paskett@osumc.edu
Ohio State University Comprehensive Cancer Center
Electra D. Paskett
Ohio State University Comprehensive Cancer Center
Interventions
  • Other: Cancer Screening — Undergo cancer screening
  • Other: Discussion — Participate in discussions
  • Other: Educational Activity — Receive coaching calls
  • Other: Educational Intervention — Receive educational materials
  • Behavioral: Focus Group — Participate in focus group
Study Locations (1 sites)
Ohio State University Comprehensive Cancer Center, Columbus, Ohio 43210 United States
Eligibility Criteria
Inclusion Criteria: * Level 1 is the health clinics (Helping Hands \[pilot\]; 6 Lower Lights clinics). Clinics are eligible if they provide preventive health care to residents of the targeted census tracts. * Level 2 focuses on health care providers (physicians, nurses, physician assistants \[PA\]/nurse practitioners \[NPs\]) and office staff practicing at participating clinics who are involved in the screening and/or screening referral process (determined by individual clinical sites) and can speak, read, and write English * Patients (Level 3) are the recipients of health care and screening interventional strategies implemented by clinics and providers. * Level 4 is the community to include residents in targeted census tracts around each clinic.
Conditions Breast Cancer, Sentinel Lymph Node
Phase PHASE2
Enrollment 220
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-03
Study Details Design, interventions, and primary outcomes

About This Study

The overall aim is to demonstrate that the use of superparamagnetic iron oxide nanoparticles (SPIO) as a tracer in an ultra-low dose (0.1 ml) is non-inferior for sentinel lymph node (SLN) detection in patients with breast cancer compared to the dual technique using Tc99m +/- blue dye, and to evaluate MRI breast artefacts and skin staining over time.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Drug: Superparamagnetic Iron Oxide — Superparamagnetic iron oxide (SPIO) consists of an iron oxide nanoparticle core and a hydrophilic coating to make it biocompatible and colloidal stable in a suspension. In this study injected intradermally in an ultra-low dose
  • Device: Technetium99 — Technetium99 +/- blue dye is injected per routine as a comparator and as back up.

Primary Outcomes

  • SLN detection rate for Magtrace 0.1 ml and for dual technique (Tc99 +/- blue dye) measured as per cent of patients where a SLN is identified using either the magnetic or the dual technique. (During the procedure)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2023-01-01
Completion: 2027-07-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 220 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Vastra Gotaland Region
Principal Investigators:
  • Fredrik Wärnberg (PRINCIPAL_INVESTIGATOR) - Sahlgrenska University Hospital
Contact Information
Study Contact:
Fredrik Wärnberg
+4631823931
fredrik.warnberg@vgregion.se
Interventions
  • Drug: Superparamagnetic Iron Oxide — Superparamagnetic iron oxide (SPIO) consists of an iron oxide nanoparticle core and a hydrophilic coating to make it biocompatible and colloidal stable in a suspension. In this study injected intradermally in an ultra-low dose
  • Device: Technetium99 — Technetium99 +/- blue dye is injected per routine as a comparator and as back up.
Study Locations (1 sites)
Sahlgrenska Iniversity Hospital, Gothenburg, 41345 Sweden
Eligibility Criteria
Inclusion Criteria: * Planned for sentinel lymph node biopsy at (or after) breast surgery * Signed and dated written informed consent before the start of specific protocol procedures Exclusion Criteria: * Pregnant or breast-feeding * Iron overload disease * Known hypersensitivity to iron, dextran compounds or blue dye. * Inability to understand given information and give informed consent or undergo study procedures
Conditions Breast Cancers
Phase NA
Enrollment 112
Locations 9 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-03
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to evaluate the efficacy and safety of oral paclitaxel plus fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in the neoadjuvant treatment of HER2+ breast cancer patients.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Paclitaxel oral solution plus Subcutaneous Pertuzumab/Trastuzumab — Patients who meet the inclusion criteria will be enrolled and given paclitaxel oral solution and subcutaneous pertuzumab/trastuzumab for neoadjuvant treatment. Paclitaxel oral solution: 200mg/m2 po bid, D1,D8,D15, q3w. Subcutaneous pertuzumab/trastuzumab: 1200 mg pertuzumab plus 600 mg trastuzumab loading dose in 15 mL, followed by 600 mg pertuzumab plus 600 mg trastuzumab maintenance doses in 10 mL, q3w.

Primary Outcomes

  • Total Pathological Complete Response(tpCR) (Approximately 6 months from first dose of study drug following surgery or early withdrawal, whichever occurred first (Surgery was performed within 6 weeks after neoadjuvant treatment))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-08-15
Completion: 2029-06-30
Eligibility
Age: 18 Years – 75 Years
Sex: ALL
Volunteers: false
Enrollment: 112 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Collaborators: Peking University Cancer Hospital & Institute, Peking University Shenzhen Hospital, Hainan People's Hospital, The Affiliated Hospital Of Guizhou Medical University, Nanfang Hospital, Southern Medical University, Guangdong Women and Children Hospital, Affiliated Cancer Hospital of Shantou University Medical College, First Affiliated Hospital of Wenzhou Medical University, Cancer Hospital of Guangxi Medical University
Principal Investigators:
  • Qiang Liu, PhD (PRINCIPAL_INVESTIGATOR) - Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Contact Information
Study Contact:
Qiang Liu, PhD
86-13922251256
liuqiang_sysu@163.com
Yudong Li, PhD
86+15989295289
649046236@qq.com
Zhaoqing Fan
+86-10-88197838
zhqfan@sina.com
Peking University Cancer Hospital
Interventions
  • Drug: Paclitaxel oral solution plus Subcutaneous Pertuzumab/Trastuzumab — Patients who meet the inclusion criteria will be enrolled and given paclitaxel oral solution and subcutaneous pertuzumab/trastuzumab for neoadjuvant treatment. Paclitaxel oral solution: 200mg/m2 po bid, D1,D8,D15, q3w. Subcutaneous pertuzumab/trastuzumab: 1200 mg pertuzumab plus 600 mg trastuzumab loading dose in 15 mL, followed by 600 mg pertuzumab plus 600 mg trastuzumab maintenance doses in 10 mL, q3w.
Study Locations (9 sites)
Peking University Cancer Hospital, Beijing, Beijing Municipality China
Guangdong Women and children Hospital, Guangzhou, Guangdong China
Sun Yat-sen Memorial Hospital, Guangzhou, Guangdong China
Cancer Hospital of Shantou University Medical College, Shantou, Guangdong China
Guangxi Provincial Cancer Hospital, Nanning, Guangxi China
The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou China
Hainan Central Hospital, Haikou, Hainan China
the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang China
Peking University Shenzhen Hospita, Shenzhen, China
Eligibility Criteria
Inclusion Criteria: Aged 18-75 years old. Histologically confirmed HER2-positive invasive breast cancer with clinical stages T1c-4, N0-3, and M0 (excluding T1cN0M0), according to the 8th American Joint Committee on Cancer (AJCC) edition BC staging system HER2 overexpression was defined as immunohistochemistry (IHC) 3+ or 2+ with HER2 gene amplification, determined by fluorescence in situ hybridization (FISH). Baseline left ventricular ejection fraction (LVEF) of ≥50%. Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1. The functional level of major organs must meet the following requirements (no blood transfusion and no use of white blood cell, red blood cell and platelet-raising drugs within 2 weeks before the first dose): * Absolute neutrophil count ≥ 1,500/mcL * Platelets ≥ 100,000/mcL * Hemoglobin ≥ 9.0 g/dL * Total bilirubin ≤ 1.5 x upper limit of normal (ULN) * Alanine aminotransferase and aspartate aminotransferase (ALT/AST) ≤1.5×ULN * Blood urea nitrogen and serum creatinine ≤1.5×ULN * Creatinine clearance (Ccr) ≥50 ml/min (Cockcroft-Gault formula) Signature of informed consent Exclusion Criteria: * History of invasive breast cancer. Bilateral breast cancer or inflammatory breast cancer . Prior excisional and/or incisional biopsy of the primary tumor and/or axillary lymph nodes. Prior systemic therapy for breast cancer. History of life-threatening hypersensitivity reactions or known hypersensitivity to any component of the investigational drug. Participation in another clinical trial of a drug or medical device within 4 weeks prior to the first dose and/or receipt of investigational drug/device during the trial. Major surgery within 28 days prior to the first dose or planned major surgery during the study period. History of other malignancies within the past 5 years, except for carcinoma in situ of the cervix, non-melanoma skin cancer, localized prostate cancer, or ductal carcinoma in situ. Active tuberculosis or other severe infectious diseases requiring systemic treatment, including but not limited to bacteremia, severe pneumonia, and other serious infections. History of immunodeficiency or autoimmune diseases, including but not limited to HIV infection (HIV antibody positive), systemic lupus erythematosus, rheumatoid arthritis, or history of organ transplantation. History of cardiovascular or cerebrovascular diseases, including: * Unstable angina; * Clinically significant arrhythmias requiring medication; * Myocardial infarction within the past 6 months; * Heart failure or second-degree or higher atrioventricular block; * Cerebral infarction (excluding lacunar infarction) or cerebral hemorrhage within the past 6 months. Poorly controlled hypertension (systolic blood pressure \>160 mmHg and/or diastolic blood pressure \>100 mmHg despite regular medication), or history of hypertensive crisis or hypertensive encephalopathy. Unsuitability for oral administration of the investigational drug, as judged by the investigator, including: * Clinically significant or uncontrolled congenital or acquired gastrointestinal diseases; * Diseases that may affect drug administration, gastric entry, or absorption (e.g., intestinal obstruction, Crohn's disease, ulcerative colitis). Pregnant or breastfeeding women; women of childbearing potential with a positive pregnancy test at screening; or those unwilling to use effective contraception during the study and for 6 months after the last dose.
Conditions Breast Cancer
Phase NA
Enrollment 350
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-03
Study Details Design, interventions, and primary outcomes

About This Study

To determine the efficacy of a multicomponent adherence intervention among participants with early-stage breast cancer on endocrine therapy and at least one oral cardiovascular disease (CVD) medication on adherence to endocrine therapy and to CVD medication at 24 weeks assessed by self-report using the Domains of Subjective Extent (DOSE)-Nonadherence questionnaire and also by pharmacy fill data assessed in the electronic health record (EHR).

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Single Group Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Behavioral: Multicomponent Adherence Intervention — The adherence intervention will be comprised of a participant preference approach in which all participants undergo a baseline pharmacist-led medication optimization session and are offered training in how to use the patient portal and freely-available smartphone reminder app.
  • Other: Usual Care — Receipt of usual care from providers

Primary Outcomes

  • Number of Participants Adherent to Endocrine Therapy (ET) and CVD Medication at 24 Weeks (24 Weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-03-02
Completion: 2028-03-31
Eligibility
Age: 18 Years – 99 Years
Sex: ALL
Volunteers: false
Enrollment: 350 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Columbia University
Collaborators: National Institute on Minority Health and Health Disparities (NIMHD)
Principal Investigators:
  • Dawn Hershman, MD (PRINCIPAL_INVESTIGATOR) - Columbia University
Contact Information
Study Contact:
Research Nurse Navigator
212-342-5162
cancerclinicaltrials@cumc.columbia.edu
Dawn Hershman, MD
212-305-1945
dlh23@columbia.edu
Columbia University Medical Center
Dawn Hershman, MD
Columbia University Medical Center
Interventions
  • Behavioral: Multicomponent Adherence Intervention — The adherence intervention will be comprised of a participant preference approach in which all participants undergo a baseline pharmacist-led medication optimization session and are offered training in how to use the patient portal and freely-available smartphone reminder app.
  • Other: Usual Care — Receipt of usual care from providers
Study Locations (1 sites)
Columbia University Medical Center, New York, New York 10032 United States
Eligibility Criteria
Inclusion Criteria: * Women or men age \>18 years * Diagnosed with stage I-III breast cancer prescribed endocrine therapy * Within 3-years of the end of early active treatment (e.g., surgery, chemotherapy not including human epidermal growth factor receptor 2 (HER2)-directed therapy, radiation) * Patients must be prescribed at least 1 antihypertensive or statin medication for CVD prevention * Self-report of at least some nonadherence ET or CVD medication on DOSE-Nonadherence Extent of Nonadherence questionnaire Exclusion Criteria: * Evidence of breast cancer recurrence * Non-English or Non-Spanish speaking * Not cognitively able to complete study requirements * Do not follow with either a primary care provider or cardiologist within the New York Presbyterian Health system's Epic EHR * Inability to provide informed consent
Conditions Breast Cancer, Chemotherapy, Sentinel Ly...
Phase NA
Enrollment 820
Locations 61 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-03
Study Details Design, interventions, and primary outcomes

About This Study

In the case of primary surgery, in patients with sentinel node involvement, it has already been shown that omitting axillary lymph node dissection (ALND), often combining axillary radiotherapy (RT), does not worsen the prognosis and does significantly reduce the appearance of lymphedema. However, patients who have received neoadjuvant systemic treatment cannot benefit from this option, even though in the majority of those who have responded well to treatment, a residual disease in the armpit is low, but there are no studies yet published that supports the possibility of not performing lymphadenectomy. The primary endpoint is to evaluate wether axillary radiotherapy (ART) presents a lower risk of lymphedema with respect to lymphadenectomy (ALND) in patients with breast cancer who, after neoadjuvant systemic treatment (NST), present the sentinel node affected. Likewise, we will evaluate recurrences and overall survival in both groups. Finally, we will analyze the quality of life of these patients.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Radiation: Axillary Radiotherapy — Axillary radiotherapy without lymphadenectomy (level I and II) + level III and supraclavicular +/- internal mammary chain
  • Procedure: Lymphadenectomy — Axillary lymph node dissection + radiotherapy level III and supraclavicular +/- internal mammary chain

Primary Outcomes

  • Disease-free survival (From date of diagnosis until the date of first documented recurrence or death, wichever came first,assessed up to 5 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2021-06-11
Completion: 2028-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 820 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Hospital Universitari de Bellvitge
Principal Investigators:
  • Maria Laplana, MDPhD (PRINCIPAL_INVESTIGATOR) - Hospital Clínico y Provincial de Barcelona
  • Amparo Garcia-Tejedor, MDPhD (PRINCIPAL_INVESTIGATOR) - Hospital Universitari de Bellvitge
Contact Information
Study Contact:
Amparo Garcia-Tejedor, MDPhD
34 + 932607695
agarciat@bellvitgehospital.cat
Gillian Lamoury
02 + 9458 8050
Gillian.Lamoury@health.nsw.gov.au
GenesisCare Mater
Gillian Lamoury
GenesisCare Mater
Interventions
  • Radiation: Axillary Radiotherapy — Axillary radiotherapy without lymphadenectomy (level I and II) + level III and supraclavicular +/- internal mammary chain
  • Procedure: Lymphadenectomy — Axillary lymph node dissection + radiotherapy level III and supraclavicular +/- internal mammary chain
Study Locations (61 sites)
GenesisCare Mater, Sydney, New South Wales 2060 Australia
GenesisCare North Shore, Sydney, New South Wales 2065 Australia
GenesisCare Frenchs Forest, Sydney, New South Wales 2086 Australia
GenesisCare Norwest, Sydney, New South Wales 2153 Australia
GenesisCare Hurstville, Sydney, New South Wales 2220 Australia
GenesisCare Campbelltown, Sydney, New South Wales 2560 Australia
Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona 08916 Spain
Instituto Catalán de Oncología de Badalona, Badalona, Barcelona 08916 Spain
Hospital Comarcal Sant Jaume de Calella, Calella, Barcelona 08370 Spain
Hospital General de Granollers, Granollers, Barcelona 08402 Spain
Eligibility Criteria
Inclusion Criteria: * T1-T4 N0/ T0-T4 N1 at diagnosis and subsidiary of neoadjuvant treatment * Post-CT SLN with ≤2 macrometastasis/micrometastasis or ITCs * Post-CT axillary response by ultrasound or MRI * Complete at least 70% of neoadjuvant chemotherapy and 6 months of endocrine treatment. Exclusion Criteria: * cN2 * ypN0 * History of breast surgery for ipsilateral cancer in the last 10 years * History of other cancer in the last 5 years, except squamous carcinoma of the skin.
Conditions Neoplasm, Breast, Heart Failure, Cardiot...
Phase Not Applicable
Enrollment 455
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-03
Study Details Design, interventions, and primary outcomes

About This Study

Rationale: In addition to surgery, effective breast cancer (BC) treatment typically requires chemotherapy, radiotherapy, or both. However, it is still unclear whether patients with BC are at increased risk of long-term cardiac dysfunction due to the adverse effects of these therapies. In a cross-sectional study in primary care, a comparison on cardiac dysfunction between 350 BC survivors and 350 age- and general practitioner (GP)- matched controls without cancer was made. In that study, BC survivors were at increased risk of mild systolic cardiac dysfunction (left ventricle ejection fraction (LVEF)\< 54%). By contrast, there was no significant difference in an LVEF \< 50% or in diastolic dysfunction. To date it remains uncertain whether the mild or subclinical dysfunction we observed predicts further cardiac deterioration. Consequently, the translation of these results into guidelines for the daily practice of the GP is unclear. Objective: The aim of the here proposed study is to clarify whether cardiac function in survivors of BC should be monitored by GPs, by assessing whether an unselected population of long-term BC survivors is at increased risk of developing cardiac dysfunction, whether in this group at-risk subgroups exists, and what factors are associated with the highest risk. Study design: A new assessment of cardiac function among women included in the BLOC-I study. This produces a longitudinal matched cohort design consisting of two cohorts in primary care. Study population: Survivors of BC, diagnosed ≥11 years ago who received chemotherapy and/or radiotherapy, and a matched reference population with no history of cancer. All participants participated in the Breast cancer Long-term Outcome of Cardiac function (BLOC-I) study. Main study parameters/endpoints: Left ventricular systolic dysfunction. Systolic cardiac dysfunction is defined as a LVEF \<54/50/45%.

Design

Study type: Observational Observational model: Cohort Time perspective: Cross Sectional

Interventions / Regimen

  • Diagnostic Test: Echocardiography — During echocardiography, the following parameters will be assessed: * Dimensions * Left ventricle function * Right ventricle function * Valves: Aorta valve and pulmonic valve * Other findings such as: frequency, rhythm, quality

Primary Outcomes

  • Left ventricular systolic dysfunction (through study completion (from Ocotober 2022 - December 2024))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2022-09-01
Completion: 2026-12-31
Eligibility
Age: Not reported
Sex: FEMALE
Volunteers: true
Enrollment: 455 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University Medical Center Groningen
Collaborators: ZonMw: The Netherlands Organisation for Health Research and Development
Contact Information
Study Contact:
Daan Brandenbarg, PhD
0031628475305
d.brandenbarg@umcg.nl
Laurine T van der Wal, MSc
0031503616154
l.t.van.der.wal@umcg.nl
Laurine T van der Wal, MSc
0031503616154
l.t.van.der.wal@umcg.nl
University Medical Center Groningen
Interventions
  • Diagnostic Test: Echocardiography — During echocardiography, the following parameters will be assessed: * Dimensions * Left ventricle function * Right ventricle function * Valves: Aorta valve and pulmonic valve * Other findings such as: frequency, rhythm, quality
Study Locations (1 sites)
University Medical Center Groningen, Groningen, 9700 AD Netherlands
Eligibility Criteria
Inclusion Criteria: * Patients who previously took part in de BLOC-I study will be included. These criteria were: * females diagnosed with stage I-III BC at least five years ago or local or locoregional recurrence of BC at least five years ago * treatment with chemotherapy and/or radiotherapy. Exclusion Criteria: * Patients unfit to travel to the hospital due to severe mental or physical illness, based on assessment by their GP. Exclusion criteria for the BC survivors in the BLOC-I study were: * metastatic disease at the time of BC diagnosis; * BC treatment after 80 years of age; * history of treatment for other types of cancer.
Conditions Breast Cancer, Prostate Cancer, Lung Can...
Phase NA
Enrollment 90
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-03
Study Details Design, interventions, and primary outcomes

About This Study

The study explores whether acupuncture as a supplement to conventional antiemetic medicine is superior in reducing the level of chemotherapy induced nausea compared to conventional anitemetic medicine alone. A total of 90 patients experiencing chemotherapy induced nausea will be allocated 1:1 to either acupuncture and antiemetic medicine or antiemetic medicine alone. The level of nausea and other cancer related symptoms will be assessed at baseline and 8 and 22 days after enrollment

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Other: Holistic acupuncture and acupressure — The intervention consists of one holistic and individualized consultation with an oncologist trained in acupuncture, in connection with outpatient chemotherapy. The consultation follows the principles of Traditional Chinese Medicine (TCM). The theoretical framework applied is Zang-Fu, which describes organ imbalances and aligns closely with Western medical understanding. Based on individual assessment and anamnesis, the patient receives acupuncture combined with acupressure. A maximum of 10 needles will be used, regardless of whether a deficiency or excess condition is identified. The acupuncture needles used are CAIR Super Silicon CSC-1, size 0.20 × 25 mm. The needles are inserted perpendicularly, except for Yin Tang, which is inserted transversely. The needles will remain in place for 25 minutes.
  • Other: Standard medical treatment — Standard treatment and care includes chemotherapy, supportive antiemetic medication, close monitoring, and management of the patient's symptoms, side effects, and overall health.

Primary Outcomes

  • Patient reported nausea assessed on the EORTC-15-PAL Scale (8 days after enrollment)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-11-17
Completion: 2027-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 90 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Vejle Hospital
Principal Investigators:
  • Mette Stie, Phd (PRINCIPAL_INVESTIGATOR) - Department of Oncology, Lillebaelt Hospital, Vejle
Contact Information
Study Contact:
Mette Stie, PhD
+4579409174
mette.stie@rsyd.dk
Nanna Nordestgaard Madsen, MScN
+4579406095
nanna.nordestgaard.madsen@rsyd.dk
Interventions
  • Other: Holistic acupuncture and acupressure — The intervention consists of one holistic and individualized consultation with an oncologist trained in acupuncture, in connection with outpatient chemotherapy. The consultation follows the principles of Traditional Chinese Medicine (TCM). The theoretical framework applied is Zang-Fu, which describes organ imbalances and aligns closely with Western medical understanding. Based on individual assessment and anamnesis, the patient receives acupuncture combined with acupressure. A maximum of 10 needles will be used, regardless of whether a deficiency or excess condition is identified. The acupuncture needles used are CAIR Super Silicon CSC-1, size 0.20 × 25 mm. The needles are inserted perpendicularly, except for Yin Tang, which is inserted transversely. The needles will remain in place for 25 minutes.
  • Other: Standard medical treatment — Standard treatment and care includes chemotherapy, supportive antiemetic medication, close monitoring, and management of the patient's symptoms, side effects, and overall health.
Study Locations (1 sites)
Department of Oncology, Vejle Hospital, Vejle, 7100 Denmark
Eligibility Criteria
Inclusion criteria * ≥ 18 years of age * Undergoing chemotherapy and experiencing nausea despite adherence to the prescribed antiemetic regimen * Understands and speaks Danish * Written and orally informed consent * Planned for treatment every 14 days * At least two chemotherapy cycles planned at the time of inclusion Exclusion Criteria: * Brain metastases * Performance status \>2
Conditions Anatomic Stage IV Breast Cancer AJCC v8,...
Phase PHASE1, PHASE2
Enrollment 34
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-03
Study Details Design, interventions, and primary outcomes

About This Study

This phase II trial studies the side effects and best dose of ivermectin in combination with balstilimab or pembrolizumab and to see how well they they work in shrinking tumors in patients with triple negative breast cancer and HR+/HER2- metastatic breast cancer that has spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as balstilimab or pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Ivermectin may help block the formation of growths that may become cancer. Giving ivermectin with balstilimab or pembrolizumab may increase the effect of balstilimab or pembrolizumab in shrinking tumors in patients with triple negative breast cancer and HR+/HER2- metastatic breast cancer. The secondary objectives of the study include evaluating the following efficacy outcomes: objective response rate (ORR), progression free survival (PFS), overall survival (OS), duration of response (DOR), clinical benefit rate (CBR), and patients' quality of life (QOL) by European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30).

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Ivermectin — Ivermectin at the assigned dose administered PO on Days 1-3, 8-10, 15-17 of each 21 day cycle (Days1-3 of each week).
  • Drug: Balstilmab — Balstilimab 300 mg administered intravenously on Day 1 of each 21 day cycle.
  • Drug: Pembrolizumab — Pembrolizumab 200 mg IV on Day 1 of each 21 day cycle

Primary Outcomes

  • Incidence of adverse events (From start of study treatment until 90 days after treatment completion)
  • Objective response rate (From start of study treatment until disease progression, intolerable toxicities, or withdrawal of consent. Assessed up to 2 years.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2023-10-13
Completion: 2026-10
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 34 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Yuan Yuan
Collaborators: Agenus Inc., Gateway for Cancer Research
Principal Investigators:
  • Yuan Yuan, MD (PRINCIPAL_INVESTIGATOR) - Cedars-Sinai Medical Center
Contact Information
Study Contact:
Clinical Trial Navigator
310-423-5842
GroupCancerTrialInformation@cshs.org
Clinical Trial Recruitment Navigator
310-423-5842
GroupCancerTrialInformation@cshs.org
Cedars-Sinai Medical Center
Yuan Yuan, MD, PhD
Cedars-Sinai Medical Center
Interventions
  • Drug: Ivermectin — Ivermectin at the assigned dose administered PO on Days 1-3, 8-10, 15-17 of each 21 day cycle (Days1-3 of each week).
  • Drug: Balstilmab — Balstilimab 300 mg administered intravenously on Day 1 of each 21 day cycle.
  • Drug: Pembrolizumab — Pembrolizumab 200 mg IV on Day 1 of each 21 day cycle
Study Locations (1 sites)
Cedars-Sinai Medical Center, Los Angeles, California 90048 United States
Eligibility Criteria
Inclusion Criteria: * Age: ≥ 18 years * Eastern Cooperative Oncology Group (ECOG) ≤ 1 * Life expectancy \> 3 months * At least one biopsy proven Triple Negative Breast Cancer (TNBC) or HR+/HER2- breast cancer in the metastatic setting. TNBC is defined by ER and PR ≤ 10% and HER2 negative (by IHC or FISH), per ASCO/CAP guidelines. In the case of discordant expression results, eligibility must be discussed and determined at the discretion of the study PI. * Patients must have progressed on 1-2 prior lines of systemic therapy (chemotherapy and/or drug-antibody conjugate) in the metastatic setting * Measurable or evaluable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions * Fully recovered from the acute toxic effects (except alopecia) to ≤ grade 2 from prior anti-cancer therapy * Patients must have adequate organ function as defined in the following: * Absolute neutrophil count (ANC) ≥ 1,500/mm\^3 * Platelets ≥ 100,000/mm\^3 * Hemoglobin ≥ 9.0 g/dL or ≥ 5.6 mmol/L. Criteria must be met without erythropoietin dependency and without packed red blood cell (pRBC) transfusion within last 2 weeks * Total serum bilirubin ≤ 1.5 x upper limit of normal (ULN) OR direct bilirubin ≤ ULN for participants with total bilirubin levels \> 1.5 x ULN * Aspartate aminotransferase (AST) ≤ 1.5 x ULN or ≤ 3 x ULN with liver metastases * Alanine aminotransferase (ALT) ≤ 1.5 x ULN or ≤ 3 x ULN with liver metastases * Creatinine ≤ 1.5 x ULN OR calculated creatinine clearance ≥ 30 mL/min for participant with creatinine levels \>1.5 x institutional ULN * International normalized ratio (INR) or prothrombin time (PT), activated partial thromboplastin time (aPTT) ≤ 1.5 x ULN unless participant is receiving anticoagulant therapy as long as PT or aPTT is within therapeutic range of intended use of anticoagulants * Women of childbearing potential (WOCBP): negative urine or serum pregnancy test \* If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required * A male participant must agree to use a contraception during the treatment period and for at least 120 days after the last dose of study treatment and refrain from donating sperm during this period * A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies: * Not a woman of childbearing potential (WOCBP) OR * Females of child-bearing potential must be willing to use effective contraception during study and for 120 days after the last dose * Written informed consent obtained from subject and ability for subject to comply with the requirements of the study. Exclusion Criteria: * Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug * Prohibited Treatments and/or Therapies: * Chemotherapy, radiation therapy, biological therapy, immunotherapy within 28 days prior to day 1 of protocol therapy * Prior radiotherapy within 2 weeks of start of study intervention. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-CNS disease * Any live vaccine within 30 days prior to the first dose of study drug. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (eg, FluMist®) are live attenuated vaccines and are not allowed * Participants on any dose of warfarin. Use of low molecular weight heparin, antithrombin agents, anti-platelet agents or factor Xa inhibitors is allowed * Participants may not be currently participating in or participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study intervention * Issues with tolerating oral medication (e.g., inability to swallow pills, malabsorption issues, ongoing nausea or vomiting during screening) * Women who are or are planning to become pregnant or breastfeed * Known allergy to any of the components within the study agents and/or their excipients * No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease free for at least three years * Participants must not have known active CNS metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable, i.e., without evidence of progression for at least 4 weeks by repeat imaging (note that the repeat imaging should be performed during study screening), clinically stable and without requirement of steroid treatment for at least 14 days prior to first dose of study intervention * History of (non-infectious) pneumonitis that required steroids or has current pneumonitis * Active infection requiring systemic therapy * Known history of Human Immunodeficiency Virus (HIV) infection * Known history of Hepatitis B (defined as Hepatitis B surface antigen \[HBsAg\] reactive) or known active Hepatitis C virus (defined as HCV RNA \[qualitative\] is detected) infection. Note: no testing for Hepatitis B and Hepatitis C is required unless mandated by local health authority * Known history of active TB (Mycobacterium tuberculosis) * Intercurrent or historic medical condition that increases subject risk in the opinion of the Investigator. Eligibility may be revisited for intercurrent medical conditions once resolution/recovery is deemed adequate by the investigator (e.g., recovery from major surgery, completion of treatment for severe infection). * Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator * Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial * Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of trial treatment * Has had an allogenic tissue/solid organ transplant * Significant cardiovascular impairment: history of congestive heart failure greater than New York Heart Association (NYHA) class II, unstable angina, myocardial infarction, or stroke within 6 months of the first dose of study drug, or cardiac arrhythmia requiring medical treatment at screening * Subjects having \> 1+ proteinuria on urine dipstick testing unless a 24-hour urine collection for quantitative assessment indicates that the urine protein is \< 1 g/24 hours * Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e., with use of disease modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment and is allowed * Any other condition that would, in the Investigator's judgment, contra